soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm align more closely with attained dose than achieved weight loss soul trial oral semaglutide cardiovascular

All four mimic a gut hormone called GLP-1 and are produced by the Danish pharmaceutical company Novo Nordisk

How Long to Wait After Stopping GLP-1 Medications Before you try to get pregnant again, you need to give these drugs time to leave your body

*Licensing is subject to change

Wegovy is indicated for lowering body weight in obese and overweight patients with at least one weight-related disease and treating metabolic dysfunction-associated steatohepatitis (MASH) in patients with mild to moderate liver fibrosis

Abstract In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes